Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks

This article was originally published in RPM Report

Executive Summary

Between big-name statins going generic and high-profile blow-ups like torcetrapib, Cordaptive and Vytorin, cholesterol drug development has been tough going. Some drug companies think the next big thing in lipid management is something different altogether: prescription-grade supplements. It may be just the thing for a risk-averse FDA.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts